$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000173728719000020 Filed on November 05, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.21M	$15.02M	$9.420M
YoY Change	14.02%	59.45%
% of Gross Profit
Research & Development	$49.76M	$40.00M	$10.87M
YoY Change	192.71%	267.94%
% of Gross Profit
Depreciation & Amortization	$1.850M	$1.330M	$500.0K
YoY Change	236.36%	166.0%
% of Gross Profit
Operating Expenses	$64.98M	$55.01M	$22.19M
YoY Change	114.17%	147.94%
Operating Profit	-$64.58M	-$55.01M	-$22.19M
YoY Change	95.41%	147.94%
Interest Expense	$3.660M	$0.00	$3.358M
YoY Change	-13.27%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$270.0K	$4.309M	-$21.31M
YoY Change		-120.22%
Pretax Income	-$61.19M	-$50.70M	-$43.50M
YoY Change	99.77%	16.56%
Income Tax	-$160.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$61.03M	-$50.74M	-$43.50M
YoY Change	100.04%	16.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$582.1K	-$496.5K	-$377.5K
COMMON SHARES
Basic Shares Outstanding	121.9M shares	121.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$530.5M	$501.2M	$244.2M
YoY Change	15.49%	105.26%
Cash & Equivalents	$175.1M	$161.0M	$83.14M
Short-Term Investments	$355.4M	$340.3M	$161.1M
Other Short-Term Assets	$11.60M	$6.200M	$3.100M
YoY Change	34.88%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$544.6M	$509.8M	$247.4M
YoY Change	16.37%	106.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.45M	$45.94M	$4.693M
YoY Change	556.77%	878.97%
Goodwill
YoY Change
Intangibles	$151.0K	$301.0K	$904.0K
YoY Change	-79.97%	-66.7%
Long-Term Investments	$63.20M	$100.7M	$154.0M
YoY Change	-75.88%	-34.61%
Other Assets	$4.618M	$3.105M	$2.307M
YoY Change	1792.62%	34.59%
Total Long-Term Assets	$173.2M	$185.8M	$187.9M
YoY Change	-43.37%	-1.12%
TOTAL ASSETS
Total Short-Term Assets	$544.6M	$509.8M	$247.4M
Total Long-Term Assets	$173.2M	$185.8M	$187.9M
Total Assets	$717.8M	$695.5M	$435.2M
YoY Change	-7.24%	59.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.250M	$8.047M	$3.083M
YoY Change	-25.03%	161.01%
Accrued Expenses	$23.80M	$25.30M	$16.80M
YoY Change	39.18%	50.6%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$139.6M
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.08M	$33.35M	$159.5M
YoY Change	12.29%	-79.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.351M	$4.785M	$7.488M
YoY Change	-35.79%	-36.1%
Total Long-Term Liabilities	$4.351M	$4.785M	$7.488M
YoY Change	-35.79%	-36.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.08M	$33.35M	$159.5M
Total Long-Term Liabilities	$4.351M	$4.785M	$7.488M
Total Liabilities	$88.78M	$75.83M	$192.6M
YoY Change	25.59%	-60.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.1M	-$335.1M	-$181.0M
YoY Change	87.27%	85.12%
Common Stock	$1.024B	$952.9M	$12.72M
YoY Change	11.99%	7389.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$629.0M	$619.7M	-$168.4M
YoY Change
Total Liabilities & Shareholders Equity	$717.8M	$695.5M	$435.2M
YoY Change	-7.24%	59.81%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$61.03M	-$50.74M	-$43.50M
YoY Change	100.04%	16.64%
Depreciation, Depletion And Amortization	$1.850M	$1.330M	$500.0K
YoY Change	236.36%	166.0%
Cash From Operating Activities	-$50.27M	-$31.93M	-$17.13M
YoY Change	134.03%	86.4%
INVESTING ACTIVITIES
Capital Expenditures	-$14.11M	-$18.40M	-$1.370M
YoY Change	968.94%	1243.07%
Acquisitions
YoY Change
Other Investing Activities	$22.05M	$97.17M	-$315.4M
YoY Change	-107.07%	-130.81%
Cash From Investing Activities	$7.920M	$78.78M	-$316.8M
YoY Change	-102.53%	-124.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	56.47M	1.570M	274.1M
YoY Change	-83.61%	-99.43%
NET CHANGE
Cash From Operating Activities	-50.27M	-31.93M	-17.13M
Cash From Investing Activities	7.920M	78.78M	-316.8M
Cash From Financing Activities	56.47M	1.570M	274.1M
Net Change In Cash	14.12M	48.42M	-59.85M
YoY Change	46.32%	-180.9%
FREE CASH FLOW
Cash From Operating Activities	-$50.27M	-$31.93M	-$17.13M
Capital Expenditures	-$14.11M	-$18.40M	-$1.370M
Free Cash Flow	-$36.16M	-$13.53M	-$15.76M
YoY Change	79.37%	-14.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	allo	Cash Received For Amounts Related To Tenant Improvement Allowances CashReceivedForAmountsRelatedToTenantImprovementAllowances	2934000	USD
CY2018Q3	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	19415000	USD
CY2019Q3	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	553350000	USD
	allo	Cash Received For Amounts Related To Tenant Improvement Allowances CashReceivedForAmountsRelatedToTenantImprovementAllowances	0	USD
CY2018Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	17121000	USD
CY2019Q3	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	25307000	USD
CY2018Q4	allo	Accrued Compensation And Related Benefits Current AccruedCompensationAndRelatedBenefitsCurrent	4111000	USD
CY2019Q3	allo	Accrued Compensation And Related Benefits Current AccruedCompensationAndRelatedBenefitsCurrent	6672000	USD
CY2018Q4	allo	Accrued Property And Equipment AccruedPropertyAndEquipment	0	USD
CY2019Q3	allo	Accrued Property And Equipment AccruedPropertyAndEquipment	4444000	USD
CY2018Q4	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	7808000	USD
CY2019Q3	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9380000	USD
CY2019Q3	allo	Allowance For Tenant Improvements AllowanceForTenantImprovements	2849000	USD
CY2018Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	714132000	USD
	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	19415000	USD
CY2019Q3	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
	allo	Convertible Preferred Stock Issued In Asset Acquisition ConvertiblePreferredStockIssuedInAssetAcquisition	111770000	USD
	allo	Convertible Preferred Stock Issued In Asset Acquisition ConvertiblePreferredStockIssuedInAssetAcquisition	0	USD
	allo	Fair Value Assets Transfers Between Levels Amount FairValueAssetsTransfersBetweenLevelsAmount	0	USD
CY2019Q3	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2019Q3	allo	Operating Leases Undiscounted Lease Payments OperatingLeasesUndiscountedLeasePayments	36231000	USD
CY2018Q4	allo	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	2356000	USD
CY2019Q3	allo	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	4124000	USD
	allo	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions	11375000	USD
	allo	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions	0	USD
	allo	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P7Y8M19D
	allo	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1	P8Y10M28D
	allo	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y6M18D
	allo	Stock Issued During Period Value Common Stock Issues StockIssuedDuringPeriodValueCommonStockIssues	5000	USD
CY2018Q3	allo	Subscriptions Receivable From Preferred Stockholders SubscriptionsReceivableFromPreferredStockholders	0	USD
CY2018Q4	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	4590000	USD
CY2019Q3	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	2842000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	121902101	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12338000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8047000	USD
CY2018Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	3108000	USD
CY2019Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	2337000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1048000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3768000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	306000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1866000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	914265000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	952820000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4639000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12695000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12835000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32189000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	1000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4639000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12695000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12834000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32189000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3358000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	302000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	452000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	101810405	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29878302	shares
CY2018Q4	us-gaap	Assets Assets	773855000	USD
CY2019Q3	us-gaap	Assets Assets	695544000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	467982000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	509757000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	743000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2174000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	320000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	713709000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	551187000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	366952000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6571000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	340254000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	261966000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	100702000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	204000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92432000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160990000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	601900000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84078000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93731000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165289000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84078000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71558000	USD
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	85214000	USD
CY2019Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	112394000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9915688	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121482671	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121895479	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121482671	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121895479	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	121000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	122000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43645000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181144000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51030000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122004000	USD
CY2018Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.85
CY2018Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	120200000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1388000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2019Q3	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2019Q3	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	4600000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3400000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-176000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	651000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2720000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.38
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11317000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26440000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	19400000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1468000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2863000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	12695000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7510000	USD
CY2018Q3	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	19400000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	754000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	301000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	3358000	USD
	us-gaap	Interest Expense InterestExpense	3358000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15016000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42261000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43497000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180996000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50702000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-123740000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-176000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3083000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3137000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1991000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3132000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-86000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-125000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3136000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	664000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4827000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	94853000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	63516000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8213000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7961000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7801000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5981000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1381000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17756000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	70691000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	75828000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	773855000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	695544000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29459000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	33354000	USD
CY2018Q4	us-gaap	Long Term Investments LongTermInvestments	261966000	USD
CY2019Q3	us-gaap	Long Term Investments LongTermInvestments	100702000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	426660000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2486000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-319410000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	156155000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23172000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87083000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-43497000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-180996000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-50735000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-123564000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	22187000	USD
	us-gaap	Operating Expenses OperatingExpenses	159796000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	55011000	USD
	us-gaap	Operating Expenses OperatingExpenses	137433000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22187000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-159796000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-55011000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-137433000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	38017000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34456000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37689000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33015000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31437000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4100000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	244000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3105000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-148000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-148000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-295000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1560000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	612000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1969000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6776000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4785000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1463000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1573000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4309000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13693000	USD
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	758000	USD
CY2019Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1938000	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	0	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	2182000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	839000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	2098000	USD
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	315399000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	162931000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1913000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36679000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49711000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8595000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8598000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8513000	USD
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2376000	USD
CY2019Q3	us-gaap	Prepaid Insurance PrepaidInsurance	114000	USD
CY2018Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	116800000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	116842000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	343300000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	299282000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	703000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	355765000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1783000	USD
	us-gaap	Profit Loss ProfitLoss	-180996000	USD
	us-gaap	Profit Loss ProfitLoss	-123564000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9643000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45943000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10870000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	133356000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39995000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95172000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	109436000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1299000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4299000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211528000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335092000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335100000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25322000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12695000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32189000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4553432	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	220151	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2781316	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7235545	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9492134	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.72
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.65
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9492134	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.65
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.31
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.03
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7M13D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y26D
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3880000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	366952000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	340254000	USD
CY2018Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	7856176	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	304576	shares
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1099000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1783000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	467000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	704000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-2000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-129440000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-168443000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	703164000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	655635000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	619716000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1905
CY2019Q3	us-gaap	Variable Lease Payment VariableLeasePayment	300000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4060419	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11048451	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	102186644	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99801001	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on</font><font style="font-family:inherit;font-size:10pt;"> November 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold </font><font style="font-family:inherit;font-size:10pt;">20,700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, which included </font><font style="font-family:inherit;font-size:10pt;">2,700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$18.00</font><font style="font-family:inherit;font-size:10pt;"> per share. As a result of the IPO, the Company received approximately </font><font style="font-family:inherit;font-size:10pt;">$343.3 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$26.1 million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> payable by the Company. At the closing of the IPO, all </font><font style="font-family:inherit;font-size:10pt;">11,743,987</font><font style="font-family:inherit;font-size:10pt;"> shares of outstanding convertible preferred stock were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">61,655,922</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and our outstanding convertible promissory notes in </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">7,856,176</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. Following the IPO, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock or preferred stock outstanding.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Need for Additional Capital</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of </font><font style="font-family:inherit;font-size:10pt;">$601.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Since inception through </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred cumulative net losses of </font><font style="font-family:inherit;font-size:10pt;">$335.1 million</font><font style="font-family:inherit;font-size:10pt;">. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC).</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forward Stock Split</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2018, the Company filed an amendment to the Company’s amended and restated certificate of incorporation to effect a forward split of shares of the Company’s common stock on a </font><font style="font-family:inherit;font-size:10pt;">1-for-5.25</font><font style="font-family:inherit;font-size:10pt;"> basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company’s then-outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001737287-19-000020-index-headers.html	Edgar Link	pending
0001737287-19-000020-index.html	Edgar Link	pending
0001737287-19-000020.txt	Edgar Link	pending
0001737287-19-000020-xbrl.zip	Edgar Link	pending
allo-20190930.xml	Edgar Link	completed
allo-20190930.xsd	Edgar Link	pending
allo-20190930x10qq319.htm	Edgar Link	pending
allo-20190930xex101.htm	Edgar Link	pending
allo-20190930xex311.htm	Edgar Link	pending
allo-20190930xex312.htm	Edgar Link	pending
allo-20190930xex321.htm	Edgar Link	pending
allo-20190930_cal.xml	Edgar Link	unprocessable
allo-20190930_def.xml	Edgar Link	unprocessable
allo-20190930_lab.xml	Edgar Link	unprocessable
allo-20190930_pre.xml	Edgar Link	unprocessable
exhibit101image1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2019 Q4 Form 10-Q Financial Statement

#000173728719000020 Filed on November 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2019 Q4 Form 10-Q Financial Statement

#000173728719000020 Filed on November 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo